



Enrollment of Phase III study for Intercell's Japanese Encephalitis Vaccine completed

Vienna (Austria), February 21, 2006 - Intercell AG (VSE, "ICLL") announced today that the recruitment for the pivotal immunogenicity Phase III trial of its Japanese Encephalitis vaccine has successfully been completed earlier than initially planned.

The pivotal Phase III trial, which is conducted at study sites in Austria, Germany and in the United States, has now reached its randomization goal of 868 subjects. The study is designed to demonstrate non-inferiority in terms of immunogenicity of the Intercell vaccine compared to JE-VAX®, in a multicenter, multinational, observer blinded, randomized parallel group design. The comparable vaccine product, JE-VAX®, is still produced on mouse brain and currently the only Japanese Encephalitis vaccine approved in the US.

In addition to the immunogenicity trial, Intercell's Phase III study program consists of several other trials, including a pivotal safety trial, a single shot trial and a co-vaccination trial for travelers. In total, more than 4000 out of approximately 5000 subjects have been randomized into the Phase III trials.

"The earlier than planned completion of recruitment for this pivotal Phase III study, which is crucial for registration, and the fast progress made within the entire Phase III program, underline the planned development strategy for our lead product candidate which is fully on track towards an expected market introduction in 2007", states Gerd Zettlmeissl, CEO of Intercell AG.

First results of these trials are expected in mid 2006. Biologics License Applications (BLA) will be made in the United States, European Union and Australia.

About Intercell's JE vaccine

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus. With over 3 billion people living in endemic areas, Japanese Encephalitis, a mosquito-borne flaviviral infection, is the leading cause of childhood encephalitis and viral encephalitis in Asia.

In a Phase II head-to-head comparison with JE-VAX®, Intercell's vaccine was shown to be:

- » Less reactogenic - both in frequency and intensity
- » More potent - higher antibody levels at all doses studied one month after the immunizations; this vaccine also showed high seroconversion rates one month after a single dose
- » More convenient - 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization



About Intercell AG

Intercell AG is a biotechnology company which focuses on the design and development of novel vaccines for prevention and treatment of diseases for which there exists substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and *S. aureus* which are in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.